Baidu
map

Eur J Cancer:瑞格菲尼/索拉非尼抑制脑膜瘤细胞的生长与侵袭

2017-12-31 MedSci MedSci原创

对于不可切除和/或侵袭性脑膜瘤的全身化疗结果,目前仍然不令人满意。PDGF受体(PDGFR)介导的有丝分裂信号传导在脑膜瘤中已被证明处于激活状态。因此,研究者们评估了临床上表征良好的受体酪氨酸激酶抑制剂瑞格菲尼/索拉非尼是否具有PDGFR的抑制作用,研究者们使用IOMM-Lee脑膜瘤细胞模型,通过磁共振成像监测,评估了瑞格菲尼/索拉非尼的细胞毒性作用,抑制增殖作用,诱导细胞凋亡以及抑制细胞侵袭的作

对于不可切除和/或侵袭性脑膜瘤的全身化疗结果,目前仍然不令人满意。PDGF受体(PDGFR)介导的有丝分裂信号传导在脑膜瘤中已被证明处于激活状态。因此,研究者们评估了临床上表征良好患者,观察受体酪氨酸激酶抑制剂瑞格菲尼/索拉非尼是否具有抑制作用,研究者们使用IOMM-Lee脑膜瘤细胞模型,通过磁共振成像监测,评估了瑞格菲尼/索拉非尼的细胞毒性作用,抑制增殖作用,诱导细胞凋亡以及抑制细胞侵袭的作用。

结果显示,瑞格菲尼/索拉非尼对恶性IOMM-Lee细胞的存活具有显著抑制作用,且能够诱导肿瘤细胞凋亡。Western Blot 结果表明这两种药物主要通过抑制ERKp44 / 42)的磷酸化,进而下调PDGFR的表达。两种药物还显示出了对肿瘤细胞运动性和侵袭性的显著抑制。在体实验中,具有原位脑膜瘤异种移植物的小鼠在瑞格菲尼/索拉非尼治疗后肿瘤体积显著缩小。对体内生长的肿瘤细胞的分析再次证明了这两种药物导致了PDGFR表达水平的显著降低。

因此瑞格菲尼/索拉非尼主要通过靶向PDGFRERK信号通路来实现抗脑膜瘤细胞的生长与侵袭的目的。

不过,梅斯医学需要提醒的是,这仅仅是细胞学水平的研究,在人体的作用还是未知的。

原始出处:

Tuchen, Marcus, et al. "Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells." European Journal of Cancer 2017 73: 9-21. doi.org/10.1016/j.ejca.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1280830, encodeId=b25e1280830de, content=<a href='/topic/show?id=a55385062c7' target=_blank style='color:#2F92EE;'>#脑膜瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85062, encryptionId=a55385062c7, topicName=脑膜瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 02 11:59:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274550, encodeId=bea62e4550d6, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Jan 01 19:08:12 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274284, encodeId=0b842e428463, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Dec 31 22:36:29 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274273, encodeId=2c5b2e42733f, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Dec 31 21:47:03 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1280830, encodeId=b25e1280830de, content=<a href='/topic/show?id=a55385062c7' target=_blank style='color:#2F92EE;'>#脑膜瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85062, encryptionId=a55385062c7, topicName=脑膜瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 02 11:59:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274550, encodeId=bea62e4550d6, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Jan 01 19:08:12 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274284, encodeId=0b842e428463, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Dec 31 22:36:29 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274273, encodeId=2c5b2e42733f, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Dec 31 21:47:03 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2018-01-01 戒馋,懒,贪

    谢谢分享学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1280830, encodeId=b25e1280830de, content=<a href='/topic/show?id=a55385062c7' target=_blank style='color:#2F92EE;'>#脑膜瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85062, encryptionId=a55385062c7, topicName=脑膜瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 02 11:59:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274550, encodeId=bea62e4550d6, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Jan 01 19:08:12 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274284, encodeId=0b842e428463, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Dec 31 22:36:29 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274273, encodeId=2c5b2e42733f, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Dec 31 21:47:03 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 131****2916

    不错的文章值得推荐

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1280830, encodeId=b25e1280830de, content=<a href='/topic/show?id=a55385062c7' target=_blank style='color:#2F92EE;'>#脑膜瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85062, encryptionId=a55385062c7, topicName=脑膜瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 02 11:59:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274550, encodeId=bea62e4550d6, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Mon Jan 01 19:08:12 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274284, encodeId=0b842e428463, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Sun Dec 31 22:36:29 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274273, encodeId=2c5b2e42733f, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Sun Dec 31 21:47:03 CST 2017, time=2017-12-31, status=1, ipAttribution=)]
    2017-12-31 戒馋,懒,贪

    谢谢分享学习了

    0

相关资讯

Lancet 重磅!瑞格菲尼在治疗晚期HCC的3期临床试验获得成功

一项国际3期临床试验发现瑞格菲尼可以提高晚期肝细胞性肝癌(HCC)病人的总生存期,这给了此前无药可治的肝癌病人一个更好的选择。这项由拜耳资助、西奈山伊坎医学院Tisch癌症研究所的研究人员领导的在21个国家152各地区进行的临床试验数据最近发表在《Lancet》上。 40%的HCC病人在晚期才得到诊断,而晚期HCC相当难治。这项临床试验中的病人在索拉菲尼治疗期间病情仍有进展,其数据表明瑞格

Baidu
map
Baidu
map
Baidu
map